In addition to the beneficial effects on glucose metabolism and body weight, GLP-1/glucagon dual receptor agonists are shown to reduce liver glycogen and fat in overweight individuals with T2D17 and reduce the urinary albumin-to-creatinine ratio in overweight individuals with T2D and CKD16. The gene discussed is ALB; the disease is type 2 diabetes mellitus.